SCHEMBL10968242

SCHEMBL10968242

O=C1CCC(c2ccc(Cc3ncc[nH]3)s2)=NN1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ PDE3B Q13370 8/20 0.36
▸ PDE3A Q14432 8/20 0.36
▸ LMNA P02545 2/20 0.36
▸ MAPT P10636 2/20 0.36
▸ NPY1R P25929 1/20 0.36
▸ NPY2R P49146 1/20 0.36
▸ TAAR1 Q96RJ0 4/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ PDE4A P27815 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ PDE4B Q07343 1/20 0.35
▸ PDE4C Q08493 1/20 0.35
▸ PDE4D Q08499 1/20 0.35
▸ HTR1A P08908 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10730668 0.80 PDE3B (0.38) SMN1; SMN2PDE3BPDE3ALMNAMAPT
SCHEMBL10724402 0.78 TAAR1 (0.35) PDE3BPDE3ATAAR1PDE4APDE4B
SCHEMBL10927112 0.76 PDE3B (0.52) SMN1; SMN2PDE3BPDE3ALMNAMAPT
SCHEMBL10727054 0.76 TAAR1 (0.36) TAAR1HTR1A
SCHEMBL10730636 0.74 TAAR1 (0.35) SMN1; SMN2PDE3BPDE3ATAAR1PDE4B
SCHEMBL10724228 0.74 CA12 (0.39) SMN1; SMN2LMNAMAPTTAAR1CYP1A2
SCHEMBL10650242 0.72 SMN1; SMN2 (0.41) SMN1; SMN2PDE3BPDE3ALMNAMAPT
SCHEMBL10648684 0.71 SMN1; SMN2 (0.43) SMN1; SMN2PDE3BPDE3ALMNAMAPT
SCHEMBL10650433 0.71 HRH3 (0.46) SMN1; SMN2PDE3BPDE3ALMNAMAPT
SCHEMBL11114157 0.71 PDE3B (0.47) PDE3BPDE3ALMNATAAR1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0071059-B1 6-(5-(OMEGA-(1-IMIDAZOLYL)-ALKYL)-THIEN-2-YL)-3-OXO-2,3,4,5-TETRAHYDROPYRIDAZINES AND THEIR ACID-ADDITION SALTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOUNDS CONTAINING THEM A. Nattermann & Cie. GmbH (DE) 1986-09-24 — — EP claimed
US-4504479-A 6-{5-[ω-(1-Imidazolyl)-alkyl]-thien-2-yl}-3-oxo-2,3,4,5-tetrahydro-pyridazines and acid addition salts thereof and a process for the treatment of inflammatory atherosclerotic and thrombo-embolic, illnesses in humans A. NATTERMANN & CIE GMBH (DE) 1985-03-12 — — US claimed
EP-0071059-A2 6-(5-(Omega-(1-imidazolyl)-alkyl)-thien-2-yl)-3-oxo-2,3,4,5-tetrahydropyridazines and their acid-addition salts, process for their preparation and pharmaceutical compounds containing them A. Nattermann & Cie. GmbH (DE) 1983-02-09 — — EP claimed
EP-0071059-B1 6-(5-(OMEGA-(1-IMIDAZOLYL)-ALKYL)-THIEN-2-YL)-3-OXO-2,3,4,5-TETRAHYDROPYRIDAZINES AND THEIR ACID-ADDITION SALTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOUNDS CONTAINING THEM A. Nattermann & Cie. GmbH (DE) 1986-09-24 — — EP disclosed
US-4504479-A 6-{5-[ω-(1-Imidazolyl)-alkyl]-thien-2-yl}-3-oxo-2,3,4,5-tetrahydro-pyridazines and acid addition salts thereof and a process for the treatment of inflammatory atherosclerotic and thrombo-embolic, illnesses in humans A. NATTERMANN & CIE GMBH (DE) 1985-03-12 — — US disclosed
Send feedback